Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Pharmosa Biopharm Inc.

Clinical trials sponsored by Pharmosa Biopharm Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New inhaled therapy for lung blood pressure passes first safety hurdle Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

New inhaled therapy for lung blood pressure passes first safety hurdle

Disease control Recruiting now

This early-stage trial tests the safety of a single inhaled dose of L608 in 32 healthy volunteers. L608 is a liposomal formulation designed to treat pulmonary arterial hypertension, a condition of high blood pressure in the lungs. The study compares different doses against a plac…

Phase 1 • Sponsor: Pharmosa Biopharm Inc. • Aim: Disease control

Last updated Jul 24, 2026 00:00 UTC